NASDAQ:CLYM Climb Bio Q4 2024 Earnings Report $12.90 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$12.90 0.00 (0.00%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Climb Bio EPS ResultsActual EPS-$0.13Consensus EPS -$0.15Beat/MissBeat by +$0.02One Year Ago EPSN/AClimb Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AClimb Bio Announcement DetailsQuarterQ4 2024Date3/25/2025TimeBefore Market OpensConference Call DateTuesday, March 25, 2025Conference Call Time11:30AM ETUpcoming EarningsClimb Bio's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Climb Bio Earnings HeadlinesClimb Bio Appoints Breanna O’Reilly to BoardJuly 1, 2026 | tipranks.comClimb Bio Inc CLYMJuly 1, 2026 | morningstar.comMALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), Climb Bio (CLYM) and Ionis Pharmaceuticals (IONS)June 27, 2026 | theglobeandmail.comClimb Bio (NASDAQ:CLYM) Sets New 52-Week High - Still a Buy?June 25, 2026 | americanbankingnews.comClimb Bio outlines 2026 clinical milestones and cash runwayJune 24, 2026 | theglobeandmail.comSee More Climb Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Climb Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Climb Bio and other key companies, straight to your email. Email Address About Climb BioClimb Bio (NASDAQ:CLYM) Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need. At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling. This integrated system enables rapid identification, optimization and high-throughput screening of novel protein candidates, accelerating the transition from target validation to preclinical development while maintaining stringent quality and manufacturability criteria. Climb Bio has assembled a portfolio of preclinical programs that leverage its platform to generate next-generation biologics in immuno-oncology and related disease areas. The company is advancing these assets through lead optimization and IND-enabling studies, with a view toward first-in-human clinical trials. By focusing on modalities that can modulate immune responses and tumor microenvironments, Climb Bio aims to create differentiated therapeutic candidates with broad applicability. Headquartered in the greater Boston area, a major hub for life science innovation, Climb Bio operates dedicated research laboratories and maintains a leadership team with extensive experience in biopharmaceutical R&D and strategic partnerships. Looking ahead, the company plans to expand its pipeline through collaborations with academic institutions and industry partners, positioning its platform to address additional disease targets and serve global markets.View Climb Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
